What NMN and NR longevity supplements actually do in human trials

The supplements sold as NMN and NR do reliably raise the molecule they promise to raise, and they appear to be safe to take for a few weeks to a few months [s1][s5]. What the human trials do not show is that raising it changes anything a buyer cares about — not muscle, not blood sugar, not blood pressure, and not any credible measure of how old the body is [s4][s5]. That gap, between a real biochemical effect and an absent clinical one, is the whole story of this product category.

NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are precursors to NAD+, a coenzyme central to how cells make energy and repair DNA. NAD+ falls with age, and reversing that decline is the mechanistic pitch behind a supplement industry that markets these compounds for cellular energy, healthier ageing and "biological age" reversal. The mechanism is real; the marketing runs far ahead of what has been tested in people.

The precursors do raise NAD+

The strongest thing the trials establish is pharmacological, not clinical. In a randomised, multicentre, double-blind trial, 80 healthy middle-aged adults took placebo or 300, 600 or 900 mg of NMN once daily for 60 days; blood NAD concentrations rose significantly in every NMN group at both day 30 and day 60 versus placebo and baseline (all p ≤ 0.001), and were highest at 600 mg and 900 mg [s1]. A separate crossover trial of nicotinamide riboside in healthy middle-aged and older adults similarly found the vitamin well tolerated and effective at stimulating NAD+ metabolism [s2]. On the narrow question the industry leads with — does the pill get into you and lift NAD+ — the answer is yes.

The clinical benefits mostly do not appear

The trouble starts when trials look past the biomarker. A 2025 systematic review and meta-analysis pooled the randomised trials of NMN and NR against placebo in older adults (mean ages ranging from 60.9 to 83 years) and tested their effect on the things that define ageing muscle [s4]. NMN showed no significant effect on skeletal muscle index (mean difference −0.42, 95% CI −0.99 to 0.14), on handgrip strength, or on gait speed (mean difference −0.01, 95% CI −0.08 to 0.06); a narrative synthesis found no improvement in knee-extension strength, the short physical performance battery, or thigh muscle mass either [s4]. Some individual trials report brighter results — the 60-day NMN trial found longer six-minute walking distances in all treated groups versus placebo (all p < 0.01) [s1] — but the pooled picture across trials is a null for the outcomes that matter to a frail older adult.

Metabolism tells the same story once trials are combined. A 2026 systematic review restricted to randomised trials of oral NMN found 15 eligible studies, with doses spanning 250 to 2,000 mg a day and durations from 14 days to 24 weeks [s5]. It found no significant effect on body weight, body-mass index, fasting glucose, HbA1c, lipid profiles or systolic blood pressure; diastolic blood pressure fell slightly and insulin resistance showed only a non-significant downward trend [s5]. The most-cited positive metabolic result — that NMN raised muscle insulin sensitivity in postmenopausal women with prediabetes who were overweight or obese — comes from a single 10-week trial in one specific population, not a general anti-ageing effect [s3].

"Biological age" is the weakest claim of all

The claim likeliest to close a sale — that the supplement makes you biologically younger — rests on the softest evidence. The 60-day NMN trial reported that a "blood biological age," calculated with a consumer web tool called the Aging.Ai 3.0 calculator, rose in the placebo group and stayed unchanged in the treated groups, producing a significant between-group difference [s1]. An age estimate from a free online calculator is not a validated ageing clock, and "did not rise" is a long way from "reversed." No trial has shown NMN or NR extending life or preventing an age-related disease in humans; the animal lifespan data that anchor the marketing have not been reproduced as human outcomes [s4][s5].

What is actually established

Stack the evidence and it is short. NMN and NR raise NAD+ and are well tolerated over the studied periods, with no clear increase in adverse events or liver-enzyme abnormalities [s1][s5]. Beyond that, the randomised human record is a run of null or population-specific results, and the flagship "younger" claim leans on a web calculator [s1][s4][s5]. That is a reasonable safety profile attached to an unproven benefit — which is a different product from the one the label describes. The same distance between a plausible mechanism and a missing outcome recurs across this section: it is visible in NAD+ IV drips, in the trials of urolithin A for muscle, and in what the evidence does and does not support for ageing muscle generally.